Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

Efficacy of Activated Recombinant Human Factor VII in Healthy Volunteers Treated for Punch Biopsy Mediated Bleeding

Phase 1

Terminated

Conditions: Haemostasis
Healthy

Interventions: Drug: clopidogrel
Drug: eptacog alfa (activated)
Drug: placebo

First Posted Date: 2012-03-23

Last Posted Date: 2016-11-23

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 91

Registration Number: NCT01561950

Locations: 🇺🇸
Novo Nordisk Investigational Site, Neptune, New Jersey, United States

Use of Activated Recombinant Human Factor VII to Reduce Bleeding Caused by Warfarin Treatment

Phase 1

Completed

Conditions: Haemostasis
Healthy

Interventions: Drug: eptacog alfa (activated)
Drug: warfarin
Drug: placebo

First Posted Date: 2012-03-23

Last Posted Date: 2016-11-25

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 127

Registration Number: NCT01561937

Locations: 🇺🇸
Novo Nordisk Investigational Site, Overland Park, Kansas, United States

Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Allogeneic Stem Cell Transplantation

Phase 2

Completed

Conditions: Acquired Bleeding Disorder
Bleeding During/Following Surgery

Interventions: Procedure: standard therapy
Drug: activated recombinant human factor VII
Drug: placebo

First Posted Date: 2012-03-23

Last Posted Date: 2017-01-11

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 100

Registration Number: NCT01562158

Locations: 🇬🇧
Novo Nordisk Investigational Site, Manchester, United Kingdom

Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery

Phase 4

Completed

Conditions: Congenital Bleeding Disorder
Haemophilia B With Inhibitors
Haemophilia A With Inhibitors

Interventions: Drug: activated recombinant human factor VII
Other: factor IX
Drug: factor VIII

First Posted Date: 2012-03-23

Last Posted Date: 2023-12-29

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 36

Registration Number: NCT01561391

Locations: 🇺🇸
Novo Nordisk Investigational Site, Houston, Texas, United States

Study to Assess the Safety and Tolerability of MEDI5117 in Rheumatoid Arthritis Patients

Phase 1

Terminated

Conditions: Rheumatoid Arthritis

Interventions: Biological: MEDI5117 Placebo
Biological: MEDI5117

First Posted Date: 2012-03-21

Last Posted Date: 2021-02-09

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 39

Registration Number: NCT01559103

Locations: 🇬🇧
Novo Nordisk Investigational Site, Belfast, United Kingdom

Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep Apnoea

Phase 3

Completed

Conditions: Obesity
Obstructive Sleep Apnoea
Metabolism and Nutrition Disorder

Interventions: Drug: placebo
Drug: liraglutide

First Posted Date: 2012-03-19

Last Posted Date: 2017-11-01

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 359

Registration Number: NCT01557166

Locations: 🇨🇦
Novo Nordisk Investigational Site, Toronto, Ontario, Canada

Investigation of the Pharmacokinetics of NNC172-2021, at Two Different Dose Levels, in Healthy Japanese Subjects

Phase 1

Completed

Conditions: Congenital Bleeding Disorder
Haemophilia B
Haemophilia A
Healthy

Interventions: Drug: NNC172-2021
Drug: placebo

First Posted Date: 2012-03-15

Last Posted Date: 2017-02-27

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 8

Registration Number: NCT01555749

Locations: 🇬🇧
Novo Nordisk Investigational Site, Harrow, United Kingdom

Observational Safety Study in Subjects With Type 2 Diabetes Mellitus Starting or Switching to Biphasic Insulin Aspart 30 Treatment

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: biphasic insulin aspart 30

First Posted Date: 2012-03-08

Last Posted Date: 2017-01-06

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 423

Registration Number: NCT01548235

Locations: 🇩🇰
Novo Nordisk Investigational Site, Copenhagen S, Denmark

Efficacy and Safety of Levemir® Used as Basal Insulin

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 1
Diabetes Mellitus, Type 2

Interventions: Drug: insulin detemir
Drug: insulin aspart

First Posted Date: 2012-03-08

Last Posted Date: 2017-01-31

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 631

Registration Number: NCT01548248

Locations: 🇸🇰
Novo Nordisk Investigational Site, Bratislava, Slovakia

Observational Study to Evaluate the Safety of Levemir® in Patients With Diabetes

Completed

Conditions: Diabetes Mellitus, Type 1
Diabetes Mellitus, Type 2
Diabetes

Interventions: Drug: insulin detemir

First Posted Date: 2012-03-07

Last Posted Date: 2016-10-28

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 1037

Registration Number: NCT01545791

Locations: 🇬🇧
Novo Nordisk Investigational Site, London, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy